Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박노진 | - |
dc.contributor.author | Jaewoo Song | - |
dc.contributor.author | 안성수 | - |
dc.date.accessioned | 2021-08-12T07:26:48Z | - |
dc.date.available | 2021-08-12T07:26:48Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 2287-979X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18196 | - |
dc.description.abstract | Background In sepsis, large scale inflammatory responses can cause extensive collateral damage to the vasculature, because both coagulation and fibrinolysis are activated unevenly. Thrombin-activatable fibrinolysis inhibitor (TAFI) plays a role in modulating fibrinolysis. Since TAFI can be activated by both thrombin and plasmin, it is thought to be affected in sepsis. Hence, activated and inactivated TAFI (TAFIa/ai) may be used to monitor changes in sepsis. Methods TAFIa/ai-specific in-house ELISA can detect only the TAFIa/ai form, because the ELISA capture agent is potato tuber carboxypeptidase inhibitor (PTCI), which has selective affinity towards only the TAFIa and TAFIai isoforms. TAFIa/ai levels in plasma from 25 patients with sepsis and 19 healthy volunteers were quantitated with the in-house ELISA. Results We observed increased TAFIa/ai levels in samples from patients with sepsis (48.7±9.3 ng/mL) than in samples from healthy individuals (10.5±5.9 ng/mL). In contrast, no difference in total TAFI concentration was obtained between sepsis patients and healthy controls. The results suggest that TAFI zymogen was activated and that TAFIa/ai accumulated in sepsis. Conclusion The detection of TAFIa/ai in plasma could provide a useful and simple diagnostic tool for sepsis. Uneven activation of both coagulation and fibrinolysis in sepsis could be caused by the activation of TAFI zymogen and elevation of TAFIa/ai. TAFIa/ai could be a novel marker to monitor sepsis and other blood-related disturbances. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | 대한혈액학회 | - |
dc.title | Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis | - |
dc.title.alternative | Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 박노진 | - |
dc.identifier.bibliographicCitation | Blood Research, v.45, no.4, pp.264 - 268 | - |
dc.relation.isPartOf | Blood Research | - |
dc.citation.title | Blood Research | - |
dc.citation.volume | 45 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 264 | - |
dc.citation.endPage | 268 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART001503082 | - |
dc.description.journalClass | 2 | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Sepsis | - |
dc.subject.keywordAuthor | TAFI isoforms | - |
dc.subject.keywordAuthor | TAFIa | - |
dc.subject.keywordAuthor | TAFIai | - |
dc.subject.keywordAuthor | Diagnosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.